CD4 and Sepsis: These three immuno-adjuvants were selected, as their primary cellular sites of action are CD4 and CD8 T cells, and are either currently clinically approved or actively in use in ongoing clinical trials for immunotherapy of sepsis or oncology [12–19 and NCT02797431, NCT02960854, NCT02274155].